EP1814856A1 - Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes - Google Patents

Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes

Info

Publication number
EP1814856A1
EP1814856A1 EP05809312A EP05809312A EP1814856A1 EP 1814856 A1 EP1814856 A1 EP 1814856A1 EP 05809312 A EP05809312 A EP 05809312A EP 05809312 A EP05809312 A EP 05809312A EP 1814856 A1 EP1814856 A1 EP 1814856A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
aryl
heteroaryl
alkoxy
nr4r5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05809312A
Other languages
German (de)
English (en)
French (fr)
Inventor
Veronique BioFocus Discovery Limited BIRAULT
Jose Antonio BioFocus Discovery Limited BRAVO
Roger BioFocus Discovery Limited CROSSLEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0425026A external-priority patent/GB0425026D0/en
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of EP1814856A1 publication Critical patent/EP1814856A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Definitions

  • the present invention relates to a compound and a group of compounds capable of binding to the active site of protein kinase enzymes.
  • the invention relates to a compound and a group of compounds which are inhibitors of a serine/ threonine kinase more particularly Rho kinase (ROK, ROCK).
  • ROK Rho kinase
  • the invention relates to methods of treatment and use of the compounds in the manufacture of a medicament for application to a number of therapeutic indications including cardiovascular disease (coronary vasospasm, hypertensive disease, arteriosclerosis), stroke, cancer, erectile dysfunction, asthma, osteoporosis, AIDS or an ocular condition including glaucoma, age related macular degeneration, lacrimal gland disease, or diabetic retinopathy, or suppression of neurite growth and hence a condition requiring nerve cell extension and connectivity, neuronal regeneration, inducing new axonal growth and promotion of axonal (re)wiring, repairing damage to neurons in the CNS caused by trauma (eg stroke, traumatic brain injury etc.) or neurodegeneration (eg Alzheimer's, Parkinson's etc), repair and recovery from and treatment of disorders such as spinal cord injury and in reducing the subsequent effects thereof, or pain caused by nerve cell damage such as following trauma or amputation for example in the treatment of neuropathic pain.
  • cardiovascular disease coronary vaso
  • Protein kinases are a family of enzymes that catalyse the phosphorylation of hydroxyl groups in proteins. Approximately 2% of the genes encoded by the human genome are predicted to encode protein kinases. The reversible phosphorylation of specific tyrosine, serine, or threonine residues on a target protein can dramatically alter its function in several ways including activating or inhibiting enzymatic activity; creating or blocking binding sites for other proteins; altering subcellular localisation or controlling protein stability. Consequently protein kinases are pivotal in the regulation of a wide variety of cellular processes, including metabolism, cell proliferation, differentiation and survival. Of the many different cellular functions known to require the actions of protein kinases, some represent targets for therapeutic intervention for certain disease states.
  • protein tyrosine kinases are known to have a significant role in the development of many disease states including diabetes, cancer and have also been linked to a wide variety of congenital syndromes.
  • Serine threonine kinases also represent a class of enzymes, inhibitors of which are likely to have relevance to the treatment of cancer, diabetes and a variety of inflammatory cardiovascular disorders and AIDS.
  • Modulation of protein kinase activity therefore represents an attractive area for the design of new therapeutic agents. Protein kinases therefore represent a targeted intervention point in the treatment of a wide range of diseases.
  • Rho kinases ROK
  • Rho family of small GTP binding proteins contains at least 10 members including Rho A-E and G, Rac 1 and 2, Cdc42, and TClO.
  • the effector domains of RhoA, RhoB, and RhoC have the same amino acid sequence appear to have similar intracellular targets.
  • Rho kinase operates as a primary downstream mediator of Rho and exists as two isoforms ⁇ (ROCK2) and ⁇ (ROCKl).
  • ROK has a catalytic (kinase) domain in its N-terminal domain, a coiled-coil domain in its middle portion, and a putative pleckstrin-homology (PH) domain in its C-terminal domain.
  • the Rho-binding domain of ROK is localized in the C-terminal portion of the coiled-coil domain and the binding the GTP-bound form of Rho results in enhancement of kinase activity.
  • myosin-binding subunit of myosin light-chain phosphatase ERM (ezrin, radixin, moesin); adducin; intermediate filament (vimentin); the Na + -H + -exchanger, and LIM-kinase.
  • Rho/Rho-kinase-mediated pathway plays an important role in the signal transduction initiated by many agonists, including angiotensin II, serotonin, thrombin, endothelin-1, norepinephrine, platelet-derived growth factor, ATP/ADP and extracellular nucleotides, and urotensin II.
  • ROK plays an important role in various cellular functions including smooth muscle contraction, actin cytoskeleton organization, cell adhesion and motility and gene expression.
  • ROK inhibitor fasudil
  • Y-27632 compound The apparent contribution of ROK to the pathogenesis of certain disorders has highlighted this kinase as a target for therapeutic intervention in a number of disease areas.
  • the first generation ROK inhibitor, fasudil and the more recent Y-27632 compound has provided proof of concept in a variety of model systems.
  • Rho-kinase inhibitors have potential utility for the treatment of disorders caused by vascular smooth muscle hyper-constriction, including cerebral vasospasm, coronary vasospasm and hypertension.
  • the beneficial effects of fasudil in the inhibition of cerebral and coronary vasospasm have been documented and there is accumulating evidence that ROK is involved in the pathogenesis of such events.
  • ROK levels of expression and activity are significantly enhanced prior to development of symptoms in spontaneously hypertensive rats suggesting that this kinase is also involved in the pathogenesis of hypertension.
  • short-term administration of Y-27632 preferentially reduces systemic blood pressure in various models of systemic hypertension.
  • ROK has also been shown to be involved in endothelial contraction and enhancement of endothelial permeability which is thought to progress atherosclerosis.
  • the strategy of inhibiting ROK may also be useful for the treatment of other disorders associated with smooth muscle hyper-reactivity, such as bronchial asthma and glaucoma. Indeed, it has been recently demonstrated that ROK is involved in bronchial smooth muscle contraction and the regulation of aqueous humor outflow.
  • ROK is also thought to play a role in the negative regulation of bone marrow formation and that its inhibition may prove to be an appropriate new strategy for treatment of osteoporosis. Based upon rat model data, ROK inhibitors may also be useful for treatment of erectile dysfunction resulting from cavernosal smooth muscle relaxation. ROK inhibitors have also been implicated in treatment of AIDS through the proposed inhibition of HIV replication.
  • Inhibitors of this kinase have also been strongly implicated in the future treatment of cancer. It is known that constitutive activation of the Rho/ROK pathway contributes to the Ras transformation phenotype and mutations of Ras are thought to occur in as many as 25% of human tumours. Indeed pharmacological inhibition of ROK has been demonstrated to reduce both focus formation generated by Ras mutants and anchorage-independent growth in some colorectal cell lines. Evidence also exists to support a critical role for ROK in tumour cell invasion. To this end a ROK therapeutic has the potential for broad applicability to a wide range of cancer types.
  • Rho kinase is involved in the suppression of neurite growth and hence nerve cell extension and connectivity. Rho kinase inhibitors therefore have uses in neuronal regeneration, inducing new axonal growth and in promotion of axonal (re)wiring. They can therefore help in repairing damage to neurons in the CNS caused by trauma (eg stroke, traumatic brain injury etc.) or neurodegeneration (eg Alzheimer's, Parkinson's etc.). Rho kinase inhibitors are also useful in the repair and recovery from and treatment of disorders such as spinal cord injury and in reducing the subsequent effects thereof.
  • trauma eg stroke, traumatic brain injury etc.
  • neurodegeneration eg Alzheimer's, Parkinson's etc.
  • Such inhibitors are also of use in treatment of pain caused by nerve cell damage such as following trauma or amputation for example in the treatment of neuropathic pain.
  • the invention addresses or ameliorates at least one of the disadvantages of the prior art, or provides a useful alternative.
  • X, Y, Z which may be the same or different are either nitrogen; or carbon substituted with hydrogen, hydroxy, halogen, trifluoromethyl, amino, Ci -6 -aminoalkyl, Ci -6 -alkyl, Ci- 6 -alkoxy, COIMR4R5, CO 2 R4, CO 2 H, NHC0R4, NR4R5, NHS(O) 2 R4, NC(O)NR4R5, NC(0)0R4, OR4 or SR4 where R4 and R5 may be the same or different are either hydrogen, d -6 -alkyl, Ci -6 -alkoxy, Ci -6 - alkylamino, aryl, hetero or heteroaryl;
  • Rl and R2 which may be the same or different, and not to be both hydrogen, are hydrogen, aryl-Ci- 6 -alkyl optionally independently substituted with one or more of methylenedioxy, hydroxy, Ci -6 -alkylhydroxy, d -6 -alkoxy, Ci -6 - alkyl, trifluoromethyl, 0-CF 3 , halogen, CN, NO 2 , aryl, heteroaryl, amino, Ci -6 -aminoalkyl, CONR4R5, CO 2 R4, CO 2 H, NHC0R4, NR4R5, NHS(O) 2 R4, NC(0)NR4R5, NC(0)0R4, 0R4 or SR4 where R4 and R5 may be the same or different are either hydrogen, Ci -6 -alkyl, Ci -6 - alkoxy, Ci -6 -alkylamino, aryl, hetero or heteroaryl; or aryl optionally independently substituted with one or more of methylenedioxy,
  • R4 and R5 may be the same or different are either hydrogen, Ci -6 -alkyl, Ci -6 - alkoxy, Ci -6 -alkylamino, aryl, hetero or heteroaryl; or CO-aryl optionally independently substituted with one or more of methylenedioxy, hydroxy, Ci -6 -alkylhydroxy, Ci -6 -alkoxy, Ci -6 -alkyl, trifluoromethyl, 0-CF 3 , halogen, CN, NO 2 , aryl, heteroaryl, amino, C 1-6 -aminoalkyl,
  • R4 and R5 may be the same or different are either hydrogen, Ci- 6 -alkyl, Ci -6 -alkoxy, Ci -6 - alkylamino, aryl, hetero or heteroaryl; alkynyl optionally independently substituted with one or more of Ci- 6 -alkoxy, Ci -6 -alkyl, Ci -6 -alkylamino, aryl, heteroaryl, CONR4R5, CO 2 R4, CO 2 H, NHCOR4, NR4R5, NHS(O) 2 R4, NC(O)NR4R5, NC(O)OR4, OR4 or
  • R4 and R5 may . be the same or different are either hydrogen, Ci -6 -alkyl, Ci -6 -alkoxy, Ci -6 - alkylamino, aryl, hetero or heteroaryl.
  • R3 and R4 which may be the same or different, and not to be both hydrogen, are hydrogen, heteroaryl optionally independently substituted with one or more of methylenedioxy, hydroxy, Ci -6 -alkylhydroxy, Ci -6 -alkoxy, Ci -6 -alkyl, amino, amino Ci -6 -alkyl, amino Ci -6 -a Iky I hydroxy, amino C 1-6 - alkylaryl, amino C 3-8 -cycloalkyl, halogen, aryl, heteroaryl, trifluoromethyl, 0-CF 3 , CN, NO 2 , CONR4R5, CO 2 R4, CO 2 H, NHC0R4, NR4R5, NHS(O) 2 R4, NC(O)NR4R5, NC(0)0R4, 0R4 or SR4 where R4 and R5 may be the same or different are either hydrogen, Ci -6 -alkyl, Ci- 6 -alkoxy, Ci -6 -alkylamino, aryl, hetero or
  • Ci- 6 -alkyl optionally independently substituted with one or more of Ci- 6 -alkoxy, aryl, heteroaryl, C 3-8 -cycloalkyl, Cs-s-cycloalkylamine, CONR4R5, C0 2 R4, CO 2 H, NHC0R4, NR4R5, NHS(O) 2 R4, NC(0)NR4R5, NC(0)0R4, 0R4 or SR4 where R4 and R5 may be the same or different are either hydrogen, Ci -6 -alkyl, d -6 -alkoxy, Ci -6 - alkylamino, aryl, hetero or heteroaryl; or
  • C 3-8 -cycloalkyl optionally independently substituted with one or more of Ci -6 -alkoxy, Ci -6 -alkyl, Ci -6 -alkylamino, aryl, heteroaryl, CONR4R5, CO 2 R4, CO 2 H, NHC0R4, NR4R5, NHS(O) 2 R4, NC(O)NR4R5, NC(0)0R4, 0R4 or SR4 where R4 and R5 may be the same or different are either hydrogen, Ci -6 -alkyl, Ci -6 -alkoxy, Ci -6 - alkylamino, aryl, hetero or heteroaryl; or alkenyl optionally independently substituted with one or more of Ci- 6 -alkoxy, d -6 -alkyl, Ci -6 -alkylamino, aryl, heteroaryl, CONR4R5, CO 2 R4, CO 2 H, NHCOR4, NR4R5, NHS(0) 2 R4, NC(O)NR4R5, NC(O
  • R4 and R5 may be the same or different are either hydrogen, Ci -5 -alkyl, Ci- 6 -alkoxy, C x-6 - alkylamino, aryl, hetero or heteroaryl;or heterocyclyl optionally independently substituted with one or more of Ci -6 -alkoxy, C 1-6 -alkyl, Ci -6 -alkylamino, aryl, heteroaryl, CONR4R5, CO 2 R4, CO 2 H, NHC0R4, NR4R5, NHS(O) 2 R4, NC(O)NR4R5, NC(0)0R4,
  • the invention provides a method for making a compound according to a first aspect of the invention, which method comprises at least one step or a series of consecutive steps from the scheme defined herein below.
  • the invention provides a group of at least two compounds comprising or consisting of a set of structurally related compounds having the general formula I.
  • the invention provides a method for making a group of compounds according to an aspect of the invention, which method comprises at least one step or a series of consecutive steps from the scheme defined herein below.
  • the invention provides an assay comprising a group of compounds, or one or more compounds according to the invention.
  • the invention provides use of an assay according to an embodiment of the invention for identifying a compound that has therapeutic affect.
  • the invention provides a pharmaceutical composition that comprises a compound according to an embodiment of the invention or a compound identified in an assay according to an embodiment of the invention.
  • the invention provides a compound according to an embodiment of the invention for use in therapy.
  • the invention provides use of a compound according to an embodiment of the invention in the manufacture of a medicament for treatment or prophylaxis of a condition characterised by abnormal kinase activity.
  • the invention provides use of a compound according to an embodiment of the invention in the manufacture of a medicament for treatment or prophylaxis of a condition selected from cardiovascular disease (coronary vasospasm, hypertensive disease, arteriosclerosis), stroke, cancer, erectile dysfunction, asthma, osteoporosis, AIDS or an ocular condition including glaucoma, age related macular degeneration, lacrimal gland disease or diabetic retinopathy, or suppression of neurite growth and hence a condition requiring nerve cell extension and connectivity, neuronal regeneration, inducing new axonal growth and promotion of axonal (re)wiring, repairing damage to neurons in the CNS caused by trauma (eg stroke, traumatic brain injury etc.) or neurodegeneration (eg Alzheimer's, Parkinson's etc), repair and recovery from and treatment of disorders such as spinal cord injury and in reducing the subsequent effects thereof, or pain caused by nerve cell damage such as following trauma or amputation for example in the treatment of neuropathic pain.
  • cardiovascular disease coron
  • the invention provides a method of treatment of a condition characterised by abnormal kinase activity that comprises administering a pharmaceutically effective amount of a compound according to an embodiment of the invention.
  • the invention provides a method of treatment of a condition selected from cardiovascular disease (coronary vasospasm, hypertensive disease, arteriosclerosis), stroke, cancer, erectile dysfunction, asthma, osteoporosis, AIDS or an ocular condition including glaucoma, age related macular degeneration, lacrimal gland disease or diabetic retinopathy, or suppression of neurite growth and hence a condition requiring nerve cell extension and connectivity, neuronal regeneration, inducing new axonal growth and promotion of axonal (re)wiring, repairing damage to neurons in the CNS caused by trauma (eg stroke, traumatic brain injury etc.) or neurodegeneration (eg Alzheimer's, Parkinson's etc), repair and recovery from and treatment of disorders such as spinal cord injury and in reducing the subsequent effects thereof, or pain caused by nerve cell damage such as following trauma or amputation for example in the treatment of neuropathic pain that comprises administering a pharmaceutically effective amount of a compound according to an embodiment of the invention.
  • cardiovascular disease coronary
  • Rl is hydrogen or Ci -6 -alkyl optionally independently substituted with one or more of Ci -6 -alkoxy, aryl, heteroaryl, C 3-8 -cycloalkyI, Cs-s-cycloalkylamine, CONR4R5, CO 2 R4, CO 2 H, NHCOR4, NR4R5, NHS(O) 2 R4, NC(O)NR4R5, NC(O)OR4, OR4 or SR4 where R4 and R5 may be the same or different are either hydrogen, Ci -6 -alkyl, Ci -6 -alkoxy, C 1-6 -alkylamino, aryl, hetero or heteroaryl.
  • Rl is hydrogen
  • R2 is aryl-Ci -5 -alkyl optionally independently substituted with one or more of methylenedioxy, hydroxy, Ci -6 - alkylhydroxy, Ci -6 -alkoxy, Ci -6 -alkyl, trifluoromethyl, 0-CF 3 , halogen, CN, NO 2 , aryl, heteroaryl, amino, Ci -6 -aminoalkyl, CONR4R5, CO 2 R4, CO 2 H, NHC0R4, NR4R5, NHS(O) 2 R4, NC(O)NR4R5, NC(0)0R4, 0R4 or SR4 where R4 and R5 may be the same or different are either hydrogen, Ci -6 -alkyl, Ci- 6 -alkoxy, Ci -6 -alkylamino, aryl, hetero or heteroaryl.
  • R2 is heterocyclyl optionally independently substituted with one or more of Ci -6 -alkoxy, Ci -6 -alkyl, Ci -6 - alkylamino, aryl, heteroaryl, CONR4R5, CO 2 R4, CO 2 H, NHC0R4, NR4R5, NHS(O) 2 R4, NC(O)NR4R5, NC(O)OR4, 0R4 or SR4 where R4 and R5 may be the same or different are either hydrogen, Ci -6 -alkyl, Ci -6 -alkoxy, Ci -6 - alkylamino, aryl, hetero or heteroaryl More preferably, R2 is 4-chlorobenzyl, 3-hydroxybenzyl or 4-chloro, 3- fluorobenzyl.
  • R3 is hydrogen, aryl or heteroaryl optionally independently substituted with one or more of methylenedioxy, hydroxy, Ci- 6 -alkylhydroxy, Ci -6 -alkoxy, Ci- 6 -alkyl, amino, amino Ci -6 -alkyl, amino Ci- 6 -a Iky I hydroxy, amino Ci -6 -alkylaryl, amino C 3-8 -cycloalkyl, halogen, aryl, heteroaryl, trifluoromethyl, 0-CF 3 , CN, NO 2 , CONR4R5, CO 2 R4, CO 2 H, NHC0R4, NR4R5, NHS(O) 2 R4, NC(O)NR4R5, NC(O)OR4, 0R4 or SR4 where R4 and R5 may be the same or different are either hydrogen, Ci- 6 -alkyl, C 1- 6 -alkoxy, Ci- 6 -alkylamino, aryl, hetero or heteroaryl.
  • R4 is hydrogen, aryl or heteroaryl optionally independently substituted with one or more of methylenedioxy, hydroxy, Ci- 6 -alkylhydroxy, Ci -6 -alkoxy, Ci -6 -alkyl, amino, amino Ci -6 -alkyl, amino Ci- 6 -a Iky I hydroxy, amino Ci -6 -alkylaryl, amino C 3-8 -cycloalkyl, halogen, aryl, heteroaryl, trifluoromethyl, 0-CF 3 , CN, NO 2 , CONR4R5, CO 2 R4, CO 2 H, NHC0R4, NR4R5, NHS(O) 2 R4, NC(O)NR4R5, NC(0)0R4, 0R4 or SR4 where R4 and R5 may be the same or different are either hydrogen, Ci -6 -alkyl, C 1- 6 -alkoxy, Ci- 6 -alkylamino, aryl, hetero or heteroaryl.
  • a compound according to an embodiment of the invention has the structure of a compound of Table A below. Any known compound having a structural formula identical to any one of the compounds covered by the formulae of scaffolds and permitted substitutions described herein is hereby explicitly disclaimed per se.
  • an embodiment of a group of compounds according to the invention comprises compounds according to the first aspect of the invention, and said group of compounds has all or substantially all of the permitted substitutions represented by compounds therein.
  • lower alkyl denotes a straight or branched alkyl group having from 1 to 6 carbon atoms ("Ci -6 - alkyl").
  • Examples of said lower alkyl include methyl, ethyl, n-propyl, iso- propyl, n-butyl, iso-butyl, sec-butyl, t-butyl and straight- and branched- chain pentyl and hexyl.
  • Ci- 6 -alkyl For parts of the range "Ci- 6 -alkyl" all subgroups thereof are contemplated such as Ci -5 -alkyl, Ci -4 -alkyl, C 1-3 -alkyl, Ci -2 - alkyl, C 2-6 -alkyl, C 2-5 -alkyl, C 2-4 -alkyl, C 2-3 -alkyl, C 3-6 -alkyl, C 4-5 -alkyl, etc.
  • Halo-Ci- 6 -alkyl means a Ci -6 -alkyl group substituted with one or more halogen atoms.
  • aryl-Ci -6 -alkyr means a Ci -6 -alkyl group substituted with one or more aryl groups.
  • C 3-8 -cycloalkyr' denotes a cyclic alkyl group having a ring size from 3 to 8 carbon atoms.
  • examples of said cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methylcyclohexyl, cycloheptyl, and cyclooctyl.
  • C 3-8 - cycloalkyl For parts of the range "C 3-8 - cycloalkyl" all subgroups thereof are contemplated such as C 3-7 -cycloalkyl, C 3-6 -cycloalkyl, C 3-5 -CyClOaIkYl, C 3-4 -cycloalkyl, C 4-8 -cycloalkyl, C 4-7 - cycloalkyl, C 4-6 -cycloalkyl, C 4-5 -cycloalkyl, C 5-7 -cycloalkyl, C 6-7 -cycloalkyl, etc.
  • C x-6 alkoxy denotes a straight or branched alkoxy group having from 1 to 6 carbon atoms.
  • examples of said lower alkoxy include methoxy, ethoxy, n-propoxy, iso- propoxy, n-butoxy, iso-butoxy, sec-butoxy, t-butoxy and straight- and branched-chain pentoxy and hexoxy.
  • Ci- 6 -alkoxy For parts of the range "Ci- 6 -alkoxy" all subgroups thereof are contemplated such as d -5 -alkoxy, Ci -4 -alkoxy, Ci- 3 -alkoxy, Ci -2 -alkoxy, C 2 - 6 -alkoxy, C 2-5 -alkoxy, C 2-4 -alkoxy, C 2 - 3 -alkoxy, C 3- 6-alkoxy, C 4-5 -alkoxy, etc.
  • alkenyl means a straight chain or branched alkenyl radical of 2 to 6 carbon atoms and containing one or more carbon-carbon double bonds and includes but is not limited to ethylene, n-propyl-1-ene, n-propyl-2-ene, isopropylene, etc.
  • alkynyl means a straight chain or branched alkynyl radical of 2 to 6 carbon atoms and containing one or more carbon-carbon triple bonds and includes but is not limited to ethynyl, 2-methylethynyl etc.
  • aryl refers to a 3-10 membered hydrocarbon ring system having at least one aromatic ring or being fused to one or more saturated or unsaturated rings including, but not limited to phenyl, pentalenyl, indenyl, indanyl, isoindolinyl, chromanyl, naphthyl, fluorenyl, anthryl, phenanthryl and pyrenyl.
  • the aryl rings may optionally be substituted, for example with Ci_ 6 -alkyl. Examples of substituted aryl groups are benzyl and 2-methylphenyl.
  • aryloxy refers to an aryl group bonded to an oxygen atom.
  • heteroaryl refers to a 3-10 membered hydrocarbon ring system having at least one aromatic ring which contains at least one heteroatom such as O, N, or S.
  • heteroaryl groups include furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, quinazolinyl, indolyl, pyrazolyl, pyridazinyl, quinolinyl, benzofuranyl, dihydrobenzofuranyl, benzodioxolyl, benzodioxinyl, benzothiazolyl, benzothiadiazolyl, and benzotriazolyl groups.
  • the heteroaryl rings may optionally be substituted, for example with Ci -6 -alkyl.
  • Heterocyclyl means a 3-10 membered ring system containing one or more heteroatoms selected from N, O or S and includes heteroaryl.
  • the heterocyclyl system can contain one ring or may be fused to one or more saturated or unsaturated rings; the heterocyclyl can be fully saturated, partially saturated or unsaturated and includes but is not limited to heteroaryl and heterocarbocyclyl.
  • carbocyclyl or heterocyclyl groups include but are not limited to cyclohexyl, phenyl, acridine, benzimidazole, benzofuran, benzothiophene, benzoxazole, benzothiazole, carbazole, cinnoline, dioxin, dioxane, dioxolane, dithiane, dithiazine, dithiazole, dithiolane, furan, imidazole, imidazoline, imidazolidine, indole, indoline, indolizine, indazole, isoindole, isoquinoline, isoxazole, isothiazole, morpholine, napthyridine, oxazole, oxadiazole, oxathiazole, oxathiazolidine, oxazine, oxadiazine, phenazine, phenothiazine, phenoxa
  • halogen shall mean fluorine, chlorine, bromine or iodine.
  • “Pharmaceutically acceptable” means being useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes being useful for veterinary use as well as human pharmaceutical use.
  • Treatment includes prophylaxis of the named disorder or condition, or amelioration or elimination of the disorder once it has been established.
  • An effective amount refers to an amount of a compound that confers a therapeutic effect on the treated subject.
  • the therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect).
  • prodrug form means a pharmacologically acceptable derivative, such as an ester or an amide, which derivative is biotransformed in the body to form the active drug.
  • pharmacologically acceptable derivative such as an ester or an amide
  • HPLC means high performance liquid chromatography.
  • the compounds of the formula (I) may be used as such or, where appropriate, as pharmacologically acceptable salts (acid or base addition salts) thereof.
  • pharmacologically acceptable addition salts mentioned above are meant to comprise the therapeutically active non-toxic acid and base addition salt forms that the compounds are able to form.
  • Compounds that have basic properties can be converted to their pharmaceutically acceptable acid addition salts by treating the base form with an appropriate acid.
  • Exemplary acids include inorganic acids, such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid; and organic acids such as formic acid, acetic acid, propanoic acid, hydroxyacetic acid, lactic acid, pyruvic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, benzenesulfonic acid, toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid, fumaric acid, succinic acid, malic acid, tartaric acid, citric acid, salicylic acid, p-aminosalicylic acid, pamoic acid, benzoic acid, ascorbic acid and the like.
  • organic acids such as formic acid, acetic acid, propanoic acid, hydroxyacetic acid, lactic acid, pyruvic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, benzenesulfonic acid, tolu
  • Exemplary base addition salt forms are the sodium, potassium, calcium salts, and salts with pharmaceutically acceptable amines such as, for example, ammonia, alkylamines, benzathine, and amino acids, such as, e.g. arginine and lysine.
  • the term addition salt as used herein also comprises solvates which the compounds and salts thereof are able to form, such as, for example, hydrates, alcoholates and the like.
  • compositions suitable for administration typically comprise at least one compound of the invention and at least one pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carrier is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
  • compositions are usually prepared by mixing the active substance, or a pharmaceutically acceptable salt thereof, with conventional pharmaceutical excipients.
  • excipients are water, gelatin, gum arabicum, lactose, microcrystalline cellulose, starch, sodium starch glycolate, calcium hydrogen phosphate, magnesium stearate, talcum, colloidal silicon dioxide, and the like.
  • Such formulations may also contain other pharmacologically active agents, and conventional additives, such as stabilizers, wetting agents, emulsifiers, flavouring agents, buffers, and the like.
  • the formulations can be further prepared by known methods such as granulation, compression, microencapsulation, spray coating, etc.
  • the formulations may be prepared by conventional methods in the dosage form of tablets, capsules, granules, powders, syrups, suspensions, suppositories or injections.
  • Liquid formulations may be prepared by dissolving or suspending the active substance in water or other suitable vehicles. Tablets and granules may be coated in a conventional manner.
  • a pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration.
  • routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration.
  • Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS).
  • the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, 'chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum mono stearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a compound according to an embodiment of the invention) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
  • a lubricant such as magnesium stearate or Sterotes
  • a glidant such as colloidal silicon dioxide
  • the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
  • a suitable propellant e.g., a gas such as carbon dioxide, or a nebulizer.
  • Systemic administration can also be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
  • Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
  • the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
  • the compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
  • suppositories e.g., with conventional suppository bases such as cocoa butter and other glycerides
  • retention enemas for rectal delivery.
  • the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
  • the materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc.
  • Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
  • Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50.
  • Compounds which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
  • the data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans.
  • the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
  • the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
  • the therapeutically effective dose can be estimated initially from cell culture assays.
  • a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture.
  • IC50 i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms
  • levels in plasma may be measured, for example, by high performance liquid chromatography.
  • compositions can be included in a container, pack, or dispenser together with instructions for administration.
  • a compound according to an embodiment of the invention may be provided as a salt, preferably as a pharmaceutically acceptable salt of compounds of formula I.
  • pharmaceutically acceptable salts of these compounds include those derived from organic acids such as acetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, mandelic acid, methanesulphonic acid, benzenesulphonic acid and p- toluenesulphonic acid, mineral acids such as hydrochloric and sulphuric acid and the like, giving methanesulphonate, benzenesulphonate, p- toluenesulphonate, hydrochloride and sulphate, and the like, respectively or those derived from bases such as organic and inorganic bases.
  • suitable inorganic bases for the formation of salts of compounds for this invention include the hydroxides, carbonates, and bicarbonates of ammonia, lithium, sodium, calcium, potassium, aluminium, iron, magnesium, zinc and the like. Salts can also be formed with suitable organic bases.
  • bases suitable for the formation of pharmaceutically acceptable base addition salts with compounds of the present invention include organic bases which are nontoxic and strong enough to form salts.
  • Such organic bases are already well known in the art and may include amino acids such as arginine and lysine, mono-, di-, or trihydroxyalkylamines such as mono-, di-, and triethanolamine, choline, mono-, di-, and trialkylamines, such as methylamine, dimethylamine, and trimethylamine, guanidine; /V-methylglucosamine; /V-methylpiperazine; morpholine; ethylenediamine; /V-benzylphenethylamine; tris(hydroxymethyl) aminomethane; and the like.
  • amino acids such as arginine and lysine, mono-, di-, or trihydroxyalkylamines such as mono-, di-, and triethanolamine, choline, mono-, di-, and trialkylamines, such as methylamine, dimethylamine, and trimethylamine, guanidine; /V-methylglucosamine; /V-methylpiperazine; morpholine;
  • Salts of compounds according to an embodiment of the invention may be prepared in a conventional manner using methods well known in the art.
  • Acid addition salts of said basic compounds may be prepared by dissolving the free base compounds according to the first or second aspects of the invention in aqueous or aqueous alcohol solution or other suitable solvents containing the required acid.
  • a base salt of said compound may be prepared by reacting said compound with a suitable base. The acid or base salt may separate directly or can be obtained by concentrating the solution e.g. by evaporation.
  • the compounds of this invention may also exist in solvated or hydrated forms.
  • the invention also extends to prodrug of a compound according to an embodiment of the invention such as an ester or amide thereof.
  • a prodrug is a compound that may be converted under physiological conditions or by solvolysis to a compound according to an embodiment of the invention or to a pharmaceutically acceptable salt of a compound according to an embodiment of the invention.
  • a prodrug may be inactive when administered to a subject but is converted in vivo to an active compound of the invention.
  • a compound for use according to the invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All diastereomeric forms possible (pure enantiomers, tautomers, racemic mixtures and unequal mixtures of two or more enantiomers) are within the scope of the invention. Such compounds can also occur as cis- or trans-, E- or Z- double bond isomer forms. All isomeric forms and mixtures thereof are contemplated.
  • Rho kinase inhibitory activity is presented as +, + + , or + + + representing active, more active and very active based on assays conducted at 1 - 100 ⁇ M.
  • reaction mixture was diluted with ethyl acetate, washed with water, dried (MgSO 4 ), evaporated then purified on silica gel by flash chromatography eluti ⁇ g with petroleum ether: ethyl acetate (1:1) to give the desired product.
  • reaction mixture was diluted with ethyl acetate, washed with water, dried (MgSO 4 ), evaporated and purified on silica gel by flash chromatography eluting with DCM:MeOH (95:5) to give the desired product (31mg).
  • the active ingredient 1 is mixed with ingredients 2, 3, 4 and 5 for about 10 minutes.
  • the magnesium stearate is then added, and the resultant mixture is mixed for about 5 minutes and compressed into tablet form with or without film-coating.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
EP05809312A 2004-11-12 2005-11-11 Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes Withdrawn EP1814856A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0425026A GB0425026D0 (en) 2004-11-12 2004-11-12 Compounds which bind to the active site of protein kinase enzymes
GBGB0500245.6A GB0500245D0 (en) 2004-11-12 2005-01-07 Compounds which bind to the active site of protein kinase enzymes
PCT/GB2005/004358 WO2006051311A1 (en) 2004-11-12 2005-11-11 Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes

Publications (1)

Publication Number Publication Date
EP1814856A1 true EP1814856A1 (en) 2007-08-08

Family

ID=35788166

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05809312A Withdrawn EP1814856A1 (en) 2004-11-12 2005-11-11 Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes

Country Status (4)

Country Link
EP (1) EP1814856A1 (enExample)
JP (1) JP2008519814A (enExample)
CA (1) CA2585490A1 (enExample)
WO (1) WO2006051311A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8211919B2 (en) 2005-09-02 2012-07-03 Astellas Pharma Inc. Amide derivatives as rock inhibitors
US8318723B2 (en) * 2006-08-16 2012-11-27 Boehringer Ingelheim International Gmbh Pyrazine compounds, their use and methods of preparation
US8071779B2 (en) * 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
KR20100007956A (ko) 2007-05-03 2010-01-22 화이자 리미티드 나트륨 채널 조절제로서의 2-피리딘 카복스아마이드 유도체
MX2010002004A (es) 2007-08-22 2010-03-11 Irm Llc Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones con inhibidores de cinasa.
TWI504395B (zh) 2009-03-10 2015-10-21 Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
TWI461197B (zh) 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
TWI475020B (zh) 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
TW201038565A (en) 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
SG175925A1 (en) * 2009-05-15 2011-12-29 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
WO2010143169A2 (en) * 2009-06-12 2010-12-16 Société Splicos Compounds useful for treating aids
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
US8809525B2 (en) 2010-02-05 2014-08-19 Heptares Therapeutics Limited 1,2,4-triazine-4-amine derivatives
JP5605727B2 (ja) * 2010-04-06 2014-10-15 Ｊｎｃ株式会社 セレンテラジン類縁体及びセレンテラミド類縁体
HUE024870T2 (en) 2010-08-27 2016-02-29 Gruenenthal Gmbh Substituted 2-oxo and 2-thioxo-dihydroquinoline-3-carboxamides as modulators of KCNQ2 / 3
TW201211007A (en) 2010-08-27 2012-03-16 Gruenenthal Gmbh Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators
RU2595894C2 (ru) 2010-08-27 2016-08-27 Грюненталь Гмбх Замещенные 2-окси-хинолин-3-карбоксамиды в качестве модуляторов kcnq2/3
MX2013002295A (es) 2010-09-01 2013-05-09 Gruenenthal Gmbh 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
EP2640702A1 (en) * 2010-11-17 2013-09-25 Novartis AG 3-(aminoaryl)-pyridine compounds
BR112014020773A2 (pt) 2012-02-22 2020-10-27 Sanford-Burnham Medical Research Institute compostos de sulfonamida e seus usos como inibidores tnap
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
EP2990040B1 (en) 2013-04-24 2019-12-04 Kyushu University, National University Corporation Therapeutic agent for eyeground disease
TN2016000270A1 (en) 2014-01-14 2017-10-06 Millennium Pharm Inc Heteroaryls and uses thereof.
JP2017502092A (ja) 2014-01-14 2017-01-19 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヘテロアリール及びその使用
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
ES2899906T3 (es) 2015-07-06 2022-03-15 Alkermes Inc Inhibidores bicíclicos de histona desacetilasa
US12048761B2 (en) 2015-10-13 2024-07-30 Inserm (Institut National De La Santé Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
EP4088719A1 (en) 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
US11168068B2 (en) 2016-07-18 2021-11-09 Janssen Pharmaceutica Nv Tau PET imaging ligands
ES2875562T3 (es) 2017-01-11 2021-11-10 Alkermes Inc Inhibidores bicíclicos de histona desacetilasa
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
EA202191890A1 (ru) 2019-01-18 2022-02-03 Астразенека Аб Ингибиторы pcsk9 и способы их применения
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
PH12022550361A1 (en) 2019-08-14 2023-02-27 Incyte Corp Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
PE20221905A1 (es) 2019-10-11 2022-12-23 Incyte Corp Aminas biciclicas como inhibidoras de la cdk2
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
EP4626878A1 (en) 2022-12-02 2025-10-08 Neumora Therapeutics, Inc. Methods of treating neurological disorders
AR131658A1 (es) * 2023-01-30 2025-04-16 Eurofarma Laboratorios S A Hidrazidas bloqueadoras de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de los mismos y sus kits
WO2025224050A1 (en) 2024-04-22 2025-10-30 Institut National de la Santé et de la Recherche Médicale Methods of treatment of patients suffering from hypomelanosis of ito

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE309241T1 (de) * 1999-09-10 2005-11-15 Merck & Co Inc Tyrosin kinase inhibitoren
PT1330452E (pt) * 2000-09-20 2009-01-22 Ortho Mcneil Pharm Inc Derivados de pirazina como moduladores de tirosina-cinases
US7122550B2 (en) * 2002-05-23 2006-10-17 Cytopia Pty Ltd Protein kinase inhibitors
JP2007516196A (ja) * 2003-07-02 2007-06-21 ガラパゴス エヌブイ Ｒｈｏキナーゼ阻害剤としてのピラジン及びピラリジン誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006051311A1 *

Also Published As

Publication number Publication date
WO2006051311A1 (en) 2006-05-18
CA2585490A1 (en) 2006-05-18
JP2008519814A (ja) 2008-06-12

Similar Documents

Publication Publication Date Title
EP1814856A1 (en) Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
WO2005003101A2 (en) Pyrazine and pyridine derivatives as rho kinase inhibitors
TWI377198B (en) Novel pyridine derivatives and pyrimidine derivatives (3)
TWI338684B (en) Tetrahydroquinoline derivatives and a process for preparing the same
US20080194584A1 (en) Nitrogen Heteroaromatic Compounds Which Bind To The Active Site Of Protein Kinase Enzymes
CN110139865B (zh) Fgfr抑制剂
TW201704237A (zh) 適用於治療與ｋｉｔ及ｐｄｆｇｒ相關之病症的組合物
CN113788825B (zh) 作为vanin抑制剂的杂芳族化合物
JPH10503174A (ja) Ｐｄｅ ｉｖ インヒビターとして有用なトリ置換フェニル誘導体
JP7195436B2 (ja) バニン阻害剤としての複素芳香族化合物
KR20070026357A (ko) 인돌 유도체, 및 키나제 억제제, 특히 ｉｋｋ2억제제로서의 그의 용도
CN113166104A (zh) 作为vanin抑制剂的杂芳族化合物
TW201902887A (zh) 做為血漿激肽釋放酶抑制劑之雜芳基甲醯胺衍生物
HK1220457A1 (zh) 取代联芳基化合物
US20090163515A1 (en) Compounds Which Bind to the Active Site of Protein Kinase Enzymes
WO2006072792A2 (en) Compounds which bind to the active site of protein kinase enzymes
TW201619134A (zh) 取代苯基化合物
US11078161B2 (en) Rock-inhibiting compound and uses thereof
WO2003082263A1 (en) Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases
CN117304182A (zh) 一类具有嘧啶并六元环结构的化合物、包含其的药物组合物及其应用
CN115197202A (zh) 一种ezh2共价抑制剂及其制备方法和应用
HK1228894A1 (en) Derivatives of 5-benzylisoquinoline for the treatment of cardiovascular diseases
HK1257578B (en) Heteroaryl compounds and their use as therapeutic drugs
MXPA98008594A (en) Piperidines and pyrolrolidi
JPH0441143B2 (enExample)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070601

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20090805

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091216